Covalent vs. Non‐Covalent Inhibition: Tackling Drug Resistance in EGFR – A Thorough Dynamic Perspective-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Covalent vs. Non‐Covalent Inhibition: Tackling Drug Resistance in EGFR – A Thorough Dynamic Perspective

Published:2019-02-05 Issue:3 Volume:16 Page:e1800518
ISSN:1612-1872
Container-title:Chemistry & Biodiversity
language:en
Short-container-title:C&B

Author:

Akher Farideh Badichi¹,Farrokhzadeh Abdolkarim¹,Soliman Mahmoud E. S.¹

Affiliation:

1. Bio-computation and Drug Design Laboratory, School of Health SciencesUniversity of KwaZulu-Natal Westville Campus Durban 4001 South Africa

Publisher

Wiley

Subject

Molecular Biology,Molecular Medicine,General Chemistry,Biochemistry,General Medicine,Bioengineering

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cbdv.201800518

Reference82 articles.

1. P. Chen H. Xie M. C. Sekar K. Gupta A. Wells ‘Epidermal growth factor receptor-mediated cell motility: phospholipase C activity is required but mitogen-activated protein kinase activity is not sufficient for induced cell movement’ J. Cell Biol.1994 127 847–857.

2. M. Günther J. Lategahn M. Juchum E. Doring M. Keul J. Engel H. L. Tumbrink D. Rauh S. Laufer ‘Trisubstituted pyridinylimidazoles as potent inhibitors of the clinically resistant L858R/T790 M/C797S EGFR mutant: targeting of both hydrophobic regions and the phosphate binding site’ J. Med. Chem.2017 60 5613–5637.

3. J. Mendelsohn J. Baselga ‘Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer’ J. Clin. Oncol.2003 21 2787–2799.

4. S. M. Lim Y. Jeong S. Hong ‘Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR’ Future Med. Chem.2016 8 853–878.

5. J. G. Paez P. A. Jänne J. C. Lee S. Tracy H. Greulich S. Gabriel P. Herman F. J. Kaye N. Lindeman T. J. Boggon K. Naoki H. Sasaki Y. Fijii M. J. Eck W. R. Sellers B. E. Johnson M. Meyerson ‘EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy’ Science2004 304 1497–1500.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Histidine-Covalent Stapled Alpha-Helical Peptides Targeting hMcl-1;Journal of Medicinal Chemistry;2024-05-02

2. Targeted degrader technologies as prospective SARS-CoV-2 therapies;Drug Discovery Today;2024-01

3. Characterization of a Potent and Orally Bioavailable Lys-Covalent Inhibitor of Apoptosis Protein (IAP) Antagonist;Journal of Medicinal Chemistry;2023-06-01

4. Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism;Molecules;2021-11-04

5. Lysine Covalent Antagonists of Melanoma Inhibitors of Apoptosis Protein;Journal of Medicinal Chemistry;2021-10-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3